Tomuleasa C - Search Results

1

Sas V, Blag C, Zaharie G, Puscas E, Lisencu C, Andronic-Gorcea N, Pasca S, Petrushev B, Chis I, Marian M, Dima D, Teodorescu P, Iluta S, Zdrenghea M, Berindan-Neagoe I, Popa G, Man S, Colita A, Stefan C, Kojima S, Tomuleasa C. Sas V, et al. Among authors: tomuleasa c. Crit Rev Clin Lab Sci. 2019 Jun;56(4):247-259. doi: 10.1080/10408363.2019.1613629. Epub 2019 Jun 21. Crit Rev Clin Lab Sci. 2019. PMID: 31043105 Review.

2

Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma.

Tomuleasa C, Soritau O, Fischer-Fodor E, Pop T, Susman S, Mosteanu O, Petrushev B, Aldea M, Acalovschi M, Irimie A, Kacso G. Tomuleasa C, et al. Hematol Oncol Stem Cell Ther. 2011;4(2):60-6. doi: 10.5144/1658-3876.2011.60. Hematol Oncol Stem Cell Ther. 2011. PMID: 21727766 Free article.

3

Antidiabetic pharmacology: a link between metabolic syndrome and neuro-oncology?

Aldea M, Tomuleasa C, Petrushev B, Susman S, Kacso GI, Irimie A, Florian IS, Soritau O. Aldea M, et al. Among authors: tomuleasa c. J BUON. 2011 Jul-Sep;16(3):409-13. J BUON. 2011. PMID: 22006741 Review.

4

Metformin plus PIAF combination chemotherapy for hepatocellular carcinoma.

Petrushev B, Tomuleasa C, Soritau O, Aldea M, Pop T, Susman S, Kacso G, Berindan I, Irimie A, Cristea V. Petrushev B, et al. Among authors: tomuleasa c. Exp Oncol. 2012;34(1):17-24. Exp Oncol. 2012. PMID: 22453143

5

The axis of evil in the fight against cancer.

Petrushev B, Tomuleasa C, Suşman S, Sorişău O, Aldea M, Kacsó G, Buigă R, Irimie A. Petrushev B, et al. Among authors: tomuleasa c. Rom J Intern Med. 2011;49(4):319-25. Rom J Intern Med. 2011. PMID: 22568277 Review.

6

Paraneoplastic syndromes with connective tissue involvement. "It's not always lupus!".

Timis T, Berce C, Duarte-Garcia A, Petrushev B, Cristea V, Tomuleasa C. Timis T, et al. Among authors: tomuleasa c. J BUON. 2012 Jul-Sep;17(3):417-21. J BUON. 2012. PMID: 23033275 Review.

7

Sorafenib for the treatment of solid malignancies: what about the cancer microenvironment?

Tomuleasa C, Cucuianu A, Aldea M, Berindan-Neagoe I. Tomuleasa C, et al. Int J Nanomedicine. 2013;8:4043-4. doi: 10.2147/IJN.S53962. Epub 2013 Oct 23. Int J Nanomedicine. 2013. PMID: 24187496 Free PMC article. No abstract available.

8

Interplay between cancer cells, macrophages and natural killer cells may actually decide the outcome of therapy with sorafenib.

Tomuleasa C, Giannelli G, Cucuianu A, Aldea M, Paradiso A, Berindan-Neagoe I. Tomuleasa C, et al. Hepatology. 2014 Jul;60(1):430. doi: 10.1002/hep.26907. Epub 2014 May 27. Hepatology. 2014. PMID: 24338511 No abstract available.

9

Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery.

Aldea M, Craciun L, Tomuleasa C, Berindan-Neagoe I, Kacso G, Florian IS, Crivii C. Aldea M, et al. Among authors: tomuleasa c. Tumour Biol. 2014 Jun;35(6):5101-10. doi: 10.1007/s13277-014-1676-8. Epub 2014 Feb 7. Tumour Biol. 2014. PMID: 24504677 Review.

10

MRI-based identification of undifferentiated cells: looking at the two faces of Janus.

Tomuleasa C, Florian IS, Berce C, Irimie A, Berindan-Neagoe I, Cucuianu A. Tomuleasa C, et al. Int J Nanomedicine. 2014 Feb 11;9:865-6. doi: 10.2147/IJN.S58674. eCollection 2014. Int J Nanomedicine. 2014. PMID: 24596462 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

212 results

Search Page